About: Transgene (company)

An Entity of Type: Public company, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, and develops and manufactures immunotherapies for the treatment of cancer. The company has two technological platforms based on these respective approaches: myvac (therapeutic vaccines) and Invir.IO (oncolytic viruses). Transgene’s portfolio consists of four products currently in clinical development. Since January 2021, Hedi Ben Brahim has served as President and Chief Executive Officer of Transgene SA. The company is listed on the Paris Stock Exchange.

Property Value
dbo:abstract
  • Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, and develops and manufactures immunotherapies for the treatment of cancer. The company has two technological platforms based on these respective approaches: myvac (therapeutic vaccines) and Invir.IO (oncolytic viruses). Transgene’s portfolio consists of four products currently in clinical development. Since January 2021, Hedi Ben Brahim has served as President and Chief Executive Officer of Transgene SA. The company is listed on the Paris Stock Exchange. (en)
dbo:foundingYear
  • 1979-01-01 (xsd:gYear)
dbo:type
dbo:wikiPageExternalLink
dbo:wikiPageID
  • 68820503 (xsd:integer)
dbo:wikiPageLength
  • 12820 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1118533307 (xsd:integer)
dbo:wikiPageWikiLink
dbp:foundation
  • December 1979 (en)
dbp:homepage
dbp:keyPeople
  • Hedi Ben Brahim (en)
dbp:locationCity
dbp:locationCountry
dbp:name
  • Transgene S.A. (en)
dbp:type
  • Public (en)
dbp:wikiPageUsesTemplate
dcterms:subject
rdf:type
rdfs:comment
  • Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, and develops and manufactures immunotherapies for the treatment of cancer. The company has two technological platforms based on these respective approaches: myvac (therapeutic vaccines) and Invir.IO (oncolytic viruses). Transgene’s portfolio consists of four products currently in clinical development. Since January 2021, Hedi Ben Brahim has served as President and Chief Executive Officer of Transgene SA. The company is listed on the Paris Stock Exchange. (en)
rdfs:label
  • Transgene (company) (en)
owl:sameAs
prov:wasDerivedFrom
foaf:homepage
foaf:isPrimaryTopicOf
foaf:name
  • Transgene S.A. (en)
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License